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Abstract
Objective: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on
serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs).
Methods: Retrospective analysis of Ig concentrations and peripheral B cell counts in 55 AAV patients.
Results: CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to
9.17 g/L (8.04-9.90) (p=0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p=0.046) and IgA 2.58 g/L (1.71-3.48) to
1.58 g/L (1-31-2.39) (p=0.056) at a median follow-up time of 4 months. IgG remained significantly below the initial value at
14.5 months and 30 months analyses. Subsequent RTX treatment in patients that had previously received CYC resulted in
a further decline in Ig levels from pre RTX IgG 9.84 g/L (8.71-11.60) to 7.11 g/L (5.75-8.77; p=0.007), from pre RTX IgM
0.84 g/L (0.63-1.18) to 0.35 g/L (0.23-0.48; p,0.001) and from pre RTX IgA 2.03 g/L (1.37-2.50) to IgA 1.62 g/L (IQR 0.84-2.43;
p=0.365) 14 months after RTX. Treatment with RTX induced a complete depletion of B cells in all patients. After a median
observation time of 20 months median B lymphocyte counts remained severely suppressed (4 B-cells/ml, 1.25-9.5, p,0.001).
Seven patients (21%) that had been treated with CYC followed by RTX were started on Ig replacement because of severe
bronchopulmonary infections and serum IgG concentrations below 5 g/L.
Conclusions: In patients with AAVs, treatment with CYC leads to a decline in immunoglobulin concentrations. A subsequent
RTX therapy aggravates the decline in serum immunoglobulin concentrations and results in a profoundly delayed B cell
repopulation. Surveying patients with AAVs post CYC and RTX treatment for serum immunoglobulin concentrations and
persisting hypogammaglobulinemia is warranted.
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Introduction
The group of ANCA-associated vasculitides (AAVs) comprises
granulomatosis with polyangiitis (GPA, Wegener’s granulomato-
sis), microscopic polyangiitis (MPA) and Churg-Strauss syndrome
(CSS). Since 1971 cyclophosphamide (CYC) has been the standard
treatment for severe, life-threatening AAVs [1]. These diseases are
histologically characterized by a necrotizing inflammation of small
vessel walls mediated by ANCAs and cytokine primed neutrophils
[2]. Cytokine-primed neutrophils, antineutrophil cytoplasmic
antibodies (ANCA) and B lymphocytes play a significant role in
the pathogenesis of AAVs [3]. The pathogenic role of B
lymphocytes in AAVs is emphasized by the observation of
increased concentrations of BAFF in the serum of patients with
GPA [4]. Furthermore, B lymphocyte targeted therapy with
rituximab (RTX) has been shown to be effective in the induction
therapy of AAVs, as well as in the treatment of relapsing AAV
disease activity [5–7]. The standard induction therapy regimen
with CYC bears the risk of infections, infertility and malignancy.
Only very limited data are available evaluating the effect of
a combined therapy with CYC and RTX on peripheral B
lymphocyte counts and immunoglobulin concentrations over
a prolonged observation period. Such data are of considerable
interest since both therapies can potentially induce hypogamma-
globulinemia leading to an increased risk of infections [8].
Microbial factors in turn may induce vasculitic flares, worsening
the overall disease outcome [9,10]. Here, we report on changes in
serum Ig concentrations, peripheral B cell numbers and infectious
complications in AAV treated with CYC or CYC followed by
RTX.
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Inclusion Criteria
Patients recruited for this retrospective analysis regularly
attended the Department of Rheumatology, University Hospital
Freiburg. Inclusion in the analysis required a diagnosis of ANCA-
associated vasculitis (GPA, MPA, or CSS) that had been treated
with CYC or CYC and RTX. After ethics committee approval
(ethic committee of the Albert-Ludwigs-University, Freiburg, EC
Freiburg 191/11, 46/04) written informed consent was obtained
and the patients’ clinical charts were retrospectively analysed. 72
patients (32 females, 40 males) were classified as AAV (GPA,
n=58; MPA, n=5; CSS, n=9) according to the American
College of Rheumatology and the Chapel Hill Consensus Criteria
and had been treated with CYC or CYC and RTX [11–13].
Patients treated with RTX and fewer than 6 months follow-up
were excluded from the analysis (n=2), as were patients with
incomplete data set precluding immunoglobulin (Ig) or peripheral
blood B lymphocyte analysis (n=14). One patient had to be
excluded because of nephrotic syndrome (n=1) at time of Ig
analysis potentially affecting serum immunoglobulin concentra-
tions. In this patient no data on B cells after RTX were available.
Fifty-five patients (24 females, 31 males) were included in the
study. The majority had GPA (n=44), seven had CSS, and four
MPA. 91% of the patients were ANCA positive. Median age was
57 years (age range 27–79 years). For more details see Table 1.
Substitution of immunoglobulins or plasmapheresis during follow-
up led to exclusion of the patient from follow-up immunoglobulin
analyses.
AAV Patients Treated with Cyclophosphamide
Thirty-six patients were analyzed for CYC effects, 30 patients
with a diagnosis of GPA, four with CSS, and two with MPA. Data
from 32 of these patients were available for serum immunoglob-
ulin analyses and data from 22 patients were available for B cell
analyses. All but three patients were ANCA positive. Detailed
patients’ characteristics are presented in table 1. The cumulative
CYC dose was 7.88 gram (g). Table 2 summarizes the different
cumulative immunosuppressive therapy regimens before and after
the application of CYC. Intravenous immunoglobulins and
plasmapheresis were used in one patient each as immunomodu-
latory therapies. One patient did not receive immunosuppressive
maintenance therapy after cessation of CYC treatment. Fourteen
patients of the CYC analysis group were at a later time point
treated with RTX and therefore also enrolled into the RTX
analysis group.
AAV Patients Treated with Rituximab after Previous
CYC Therapy
Thirty-three patients of the study group were treated with
RTX subsequently to CYC. Patients were treated with RTX as
off-label therapy for refractory disease or had relapsed after
standard immunosuppressive therapy including CYC. Detailed
Table 1. Patients’ characteristics of the AAV cohort.
All patients CYC
# CYC+RTX p value
Patients’ characteristics
Number, n (female/male) 55 (24/31) 36 (16/20) 33 (14/19) 0.872
Age, median years (IQR) 57 (48–69.75) 58.5 (49.5–68.5) 56 (47–68.25) 0.815
Disease duration, median months (IQR) 78 (44.75–120.75) 89 (55.5–117.5) 72 (40.25–168.75) 0.564
Diagnosis, n (%)
GPA 44 (80.0) 30 (28) 28 (84.8) 0.872
MPA 4 (7.3) 2 (5.6) 2 (6.1) 0.792
CSS 7 (12.7) 4 (11.1) 3 (9.1) 0.925
ANCA status, n (%)
ANCA positive 50 (90.9) 33 (91.7) 31 (93.9) 0.728
PR3-ANCA positive 38 (69.1) 25 (69.4) 26 (78.8) 0.385
MPO-ANCA positive 6 (10.9) 4 (11.1) 3 (9.1) 0.792
Disease stage, n (%)
Localised 4 (7.3) 4 (11.1) 1 (3.0) 0.204
Systemic 51 (92.7) 32 (88.9) 32 (97.0) 0.204
Organ involvement, n (%)
Renal 25 (45.5) 13 (36.1) 19 (57.6) 0.077
Pulmonary 42 (76.4) 26 (72.2) 26 (78.8) 0.536
Ear, nose, throat (ENT) 42 (76.4) 27 (75.0) 28 (84.8) 0.317
Skin 14 (25.5) 8 (22.2) 8 (24.2) 0.850
Central nervous system 7 (12.7) 5 (13.9) 5 (15.2) 0.890
Peripheral nervous system 22 (40.0) 11 (30.6) 15 (45.5) 0.208
Characteristics of patients with ANCA-associated vasculitis analysed for effects of cyclophosphamide (CYC) and rituximab (RTX).
GPA, granulomatosis with polyangiitis (Wegener’s granulomatosis); MPA, microscopic polyangiitis; CSS, Churg-Strauss syndrome; ANCA, antineutrophil cytoplasmic
antibody; PR3, proteinase3; MPO, myeloperoxidase; IQR, interquartile range; CYC, cyclophosphamide; RTX, rituximab.
If not indicated otherwise, median and interquartile range are reported;
#14 patients of CYC analysis group were later treated with RTX and subsequently also enrolled into the RTX analysis group.
doi:10.1371/journal.pone.0037626.t001
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treatment are listed in table 1 and table 2. Cumulative CYC
dose was 14.45 g. Data from 18 patients were analysed for
changes in serum Ig concentrations after RTX treatment. In
Table 2. Treatment characteristics of the AAV cohort.
All patients (n=55) CYC (n=36)
# CYC + RTX (n=33) p value
Prednisone (mg/day) within the four week interval prior to treatment with CYC or RTX
CYC, median (IQR) 0.0 (0.0–15.0) 0.0 (0.0–18.75) 5.0 (0.0–11.25) 0.755
CYC, mean (SD) 8.8 (612.8) 8.0 (611.3) 8.4 (612.8)
RTX, median (IQR) n.a. n.a. 7.5 (5.0–12.5)
Prednisone dose (mg/day) 6, 12, and 24 months after CYC or RTX treatment
6 months, median (IQR) n.a. 7.5 (7.5–13.75) 10.0 (7.5–15.0) 0.527
12 months, median (IQR) n.a. 7.5 (6.875–10.0) 7.5 (5.0–7.5) 0.552
24 months, median (IQR) n.a. 5.0 (5.0–8.75) 5.0 (5.0–7.5) 0.587
CYC and RTX (cumulative dose in gram)
CYC dose, median (IQR) n.a. 7.88 (5.525–20.0) 14.45 (9.375–38.75) 0.012
RTX dose, median (IQR) n.a. n.a. 2.0 (1.0–5.0) n.a.
One/two/three courses, n 15/12/6
Induction therapy, n (%)
CYC 43 (78.2) 26 (72.2) 27 (81.8) 0.353
MTX 6 (10.9) 5 (13.8) 4 (12.1) 0.837
AZA 3 (5.5) 3 (8.3) 0 (0) 0.096
MMF 2 (3.6) 1 (2.8) 2 (6.1) 0.518
CSA 1 (1.8) 1 (2.8) 0 (0) 0.353
Cumulative treatment before start of CYC, n (%)
Prednisone 27 (49.1) 16 (44.4) 18 (54.5) 0.409
MTX 8 (14.5) 7 (19.4) 5 (15.2) 0.647
AZA 4 (7.3) 3 (8.3) 1 (3.0) 0.358
MMF 2 3.6) 1 (2.8) 2 (6.1) 0.518
LEF 3 (5.5) 3 (8.3) 2 (6.1) 0.728
CSA 2 (3.6) 1 (2.8) 1 (3.0) 0.967
TNFa antagonist 2 (3.6) 2 (5.6) 1 (3.0) 0.622
no immunosuppressive agent* 43 (78.2) 26 (72.2) 27 (81.8) 0.353
Cumulative treatment after start of CYC and prior to RTX treatment, n (%)
Prednisone 55 (100) 36 (100) 33 (100) 1.000
MTX 34 (61.8) 21 (58.3) 20 (60.6) 0.854
AZA 34 (61.8) 18 (50.0) 22 (66.7) 0.166
MMF 19 (34.5) 7 (19.4) 15 (45.5) 0.022
LEF 16 (29.1) 10 (27.8) 11 (33.3) 0.624
CSA 3 (5.5) 1 (2.8) 2 (6.1) 0.518
TNFa antagonist 7 (12.7) 4 (11.1) 5 (15.2) 0.628
Cumulative treatment after RTX treatment, n (%)
MTX n.a. n.a. 9 (27.3)
AZA n.a. n.a. 10 (30.3)
MMF n.a. n.a. 9 (27.3)
LEF n.a. n.a. 6 (18.2)
Previous immunotherapy, median
number (IQR)
{
n.a. 3.0 (2–4) 3.0 (1–4) 0.431
Treatment characteristics of all AAV patients, patients treated with CYC and patients treated with RTX after previous CYC therapy.
CYC, cyclophosphamide; RTX, rituximab; MTX, methotrexate; AZA, azathioprine; MMF, mycophenolate mofetil; LEF, leflunomide; CSA, cyclosporine A; IQR, interquartile
range.
*other than prednisone,
{before CYC or RTX treatment,
#14 patients of the CYC group were later treated with RTX and subsequently also enrolled in the RTX analysis group.
doi:10.1371/journal.pone.0037626.t002
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application and during follow-up were available. Twenty-four
RTX treated patients were included in the analysis of peripheral
B cell numbers.
Clinical and Laboratory Assessments
Data analyses of these patients comprised laboratory values,
evaluation of disease extent and organ involvement. All disease
stages were defined according to EULAR/EUVAS [14]. Ig serum
concentrations (normal range: IgG 7-16 g/L, IgM 0.4-2.3 g/L,
IgA 0.7-4 g/L) were determined by nephelometry (Behring
Nephelometer). The ANCA staining pattern (cytoplasmatic or
perinuclear) was assessed by indirect immunofluorescence. AN-
CA’s specificity for proteinase 3 (PR3) (Organtec) or myeloperox-
idase (MPO) (Euroimmun) was measured by enzyme-linked
immunosorbent assay (ELISA) and interpreted according to
manufacturers’ reference ranges with the upper limit of the
normal of ,10 U/ml for PR3 and ,20 U/ml for MPO.
Peripheral B lymphocytes were analyzed by 4-colour flow
cytometry (FACSCalibur, BD-Biosciences) [15]. B cell depletion
was defined as counts that were #2 B cells/ml.
Vaccination Response to Pneumococcal Polysaccharides
Four RTX treated patients were vaccinated against pneumo-
coccal polysaccharides (PneumovaxH). Specific IgG antibodies
were assayed by using a serotype-specific (serotypes 4, 5, 6B, 7F,
9V, 14, 18C, 19F, and 23F) ELISA. The assays were performed
according to World Health Organization recommendations with
reference serum 89-SF as standard [16].
Statistical Analysis
Results were compared by Wilcoxon-analysis using SigmaStat
software version 11.0 (Systat Software, Inc. SigmaStat for
Windows). All statistical tests were two-tailed and a p-value
,0.05 was considered statistically significant. When not otherwise
indicated median and interquartile range (median; IQR) are
reported.
Results
Patients’ Characteristics and Treatment
There was no difference in age, sex, ANCA status, organ
involvement, disease extent and duration between the patient
groups (Table 1). Daily prednisone doses at the time of serum
immunoglobulin measurement and median number of immuno-
suppressive agents were comparable. The cumulative CYC dose
was significantly higher in patients treated with RTX (p=0.012)
compared to patients treated with CYC only. Patients were treated
with RTX when AAV disease activity was resistant to CYC
treatment. We analysed serum immunoglobulin concentrations
immediately prior to CYC and RTX therapy. Application of an
additional course of RTX, substitution of immunoglobulins or
plasmapheresis during follow-up led to exclusion from follow-up B
lymphocyte or immunoglobulin analyses. Ig concentrations (g/L)
prior to application of CYC as well as prior to subsequent
application of RTX were within normal range (Ig concentrations
prior to CYC: IgG 12.8 g/L, IQR 8.15-15.45; IgM 1.05 g/L,
IQR 0.70-1.41; IgA 2.58 g/L, IQR 1.71-3.48; Ig concentrations
prior to RTX: IgG g/L 9.84, IQR 8.71-11.60; IgM g/L 0.84,
IQR 0.63-1.18; IgA g/L 2.03; IQR 1.37-2.50). There was no
association between low serum immunoglobulin concentrations
and renal dysfunction (as defined by creatinine .1.17 mg/dl
(p=0.952) or a decrease in the glomerular filtration rate calculated
by Cockroft-Gault). Peripheral B lymphocytes were measured one
month before and four, respectively 20 months after RTX and 20
months after CYC treatment.
Effect of Cyclophosphamide on Serum Immunoglobulin
Concentrations and Peripheral B Cell Numbers
The effect of CYC on serum immunoglobulin concentrations
was assessed in 32 patients. Serum immunoglobulin concentra-
tions were analyzed at median 4 months (n=26 patients), 14.5
months (n=20 patients) and 30 months (n=22 patients). Four
months after CYC treatment IgG and IgM concentrations had
decreased significantly (IgG 9.17 g/L, IQR 8.04-9.90, p=0.002;
IgM g/L 0.83, IQR 0.60-1.17, p=0.046; IgA 1.58 g/L, IQR 1-
31-2.39, p=0.056) and IgG remained significantly below the
initial value at 14.5 months analysis (IgG 8.74 g/L, IQR 7.43-
10.54, p=0.016; IgM 0.90 g/L, IQR 0.43-1.175, p=0.123; IgA
1.65 g/L, IQR 1.10-2.165, p=0.091) and 30 months analysis
(IgG 9.56 g/L, IQR 8,43-11.0, p=0.043; IgM 1.105 g/L, IQR
0.77-1.38, p=0.405; IgA 1.69 g/L, IQR 1.12-2.25, p=0.096)
(Figure 1a). Median number of peripheral B lymphocytes 19.5
months after CYC treatment was 62/ml (IQR 36-102/ml).
Effect of Rituximab on Serum Immunoglobulin
Concentrations after Previous CYC Treatment
The treatment with RTX after previous CYC exposure resulted
in a further significant decline in Ig concentrations at 3 month’s
analysis from 9.84 g/L (IQR 8.71-11.60) to 8.34 g/L (IQR 6.32-
9.80), and in IgM from 0.84 g/L (IQR 0.63-1.18) to 0.54 g/L
(IQR 0.31-0.80) (p=0.02 and p=0.019). The decline in IgA from
2.03 g/L (IQR 1.37-2.50) to 1.55 g/L (IQR 1.07-2.29) did not
reach statistical significance (p=0.190) (Figure 1 b). The analyses
at 11 months showed comparable results with a significant
decrease in IgG and IgM (p=0.023 and p=0.043), while the
decrease in IgA was not significant (p=0.124). After 14 months
IgG had declined to 7.11 g/L (5.75-8.77; p=0.007), IgM to
0.35 g/L (0.23-0.48; p,0.001) and IgA to 1.62 g/L (IQR 0.84-
2.43; p=0.365). In four patients the observation period after RTX
treatment was more than 36 months. In one patient IgG
concentrations returned to 12.8 g/L and peripheral B cell
numbers to 154/ml after an initially complete B cell depletion.
Two patients had persistently reduced IgG concentrations (5.57 g/
L and 6.71 g/L) and in one patient Ig concentrations stabilized at
8.54 g/L.
Patients with subsequent RTX treatment were previously
treated with a significantly higher cumulative CYC dose.
Therefore, we tested whether higher CYC doses accounted for
the more profound decrease in serum immunoglobulin levels after
RTX treatment. We compared patients treated with CYC sum
dose .15 g (median CYC 51 g, IQR 29.38-130.13) to patients
with CYC sum dose ,15 g (median CYC 8.25 g, IQR 6.63-
12.38). The difference in the decline in serum Ig concentrations
was statistically not significant between patients treated with low
CYC doses (IgG 5.54 g/L; IgM 0.29 g/L; IgA 1.49 g/L)
compared to those treated with high CYC doses (IgG 8.19 g/L,
IgM 0.49 g/L; IgA 1.20 g/L; p=n.s. for all). After CYC
treatment MMF was significantly more often used in patients that
were subsequently treated with RTX (Table 2) and MMF was also
more often used as maintenance therapy after RTX treatment
(p=0.022). To rule out that immunosuppressive therapy with
MMF accounts for low serum immunoglobulin levels after RTX
treatment, we excluded patients treated with MMF after RTX
from analysis of serum immunoglobulin concentrations. Even
when these patients were excluded a significant decrease in serum
Serum Immunoglobulins after RTX in AAV Patients
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served (data not shown).
Impaired Specific Antibody Responses and Infectious
Complications in AAV Patients
IgG concentrations in 18 of the CYC/RTX treated patients
(54%) and six of the patients without RTX treatment (21%)
dropped to serum levels below 7.0 g/L after therapy with RTX,
respectively CYC. In the RTX analysis group seven patients (21%)
had serum IgG levels even below 5.0 g/L (range: IgG 2.82–
4.59 g/L) and required regular Ig substitution therapy because of
severe bronchopulmonary infections independent of AAV activity.
Three patients suffered from recurrent episodes of bacterial
sinusitis and bronchitis. In three patients pneumonia with
infiltrates on chest x-ray, elevated C-reactive protein and elevated
procalcitonine was diagnosed, and responded rapidly to antibiotic
treatment, while immunosuppressive therapy regimen was not
changed. In one patient a mesenterial abscess formation with
extended-spectrum B lactamase strains of Klebsiella pneumoniae
and Escherichia coli occurred that prompted combined surgical
and antibiotic treatment. This patient had previously been treated
with high doses of prednisone. Pneumocystis pneumonia did not
develop in any of the patients. Only one patient in the CYC
analysis group suffered from recurrent respiratory tract infections
not related to active vasculitis and was treated with immunoglob-
ulin replacement therapy. The rationale for starting immunglo-
bulin replacement therapy were persistently reduced serum Ig
concentrations, recurrent infections and – if tested – an inadequate
antibody response to vaccinations. In four RTX treated patients
we assessed the specific antibody response after PneumovaxH
vaccination. IgG antibody titers against nine individual serotypes
were measured using an ELISA (Figure 2 a) based on the World
Health Organization recommendation. Although 3 patients had
significant titers for some pneumococcal polysaccharide (PnPS)
serotypes prior to vaccination, there was almost no increase for
any serotype in any patient after vaccination. In particular, none
of the patients showed a greater than 4-fold increase for 3
serotypes. A seroconversion from titers below 1.3 mg/ml was
absent for most pneumococcal polysaccharides. This indicates an
impaired response according to published criteria [17]. On follow-
up of the seven patients that had been started on immunoglobulin
replacement therapy, only one of these patients returned to
normal serum Ig concentrations.
B Cell Reconstitution after Therapy with CYC and RTX
Peripheral B lymphocyte counts measured immediately before
RTX were available in 23 patients, at four months analysis after
RTX treatment in 24 and at 20 months analysis after RTX
treatment in 15 patients. Application of additional courses of RTX
led to exclusion from follow-up B lymphocyte analysis. Median B
cell number prior to RTX therapy was 62/ml (IQR 34.5-108.75).
Treatment with RTX resulted in a complete depletion of B cells
(#2/ml) in all patients within four months (median 0/ml, IQR 0-2,
p,0.001). After a median observation time of 20 months (IQR
3.0-59.0) median B lymphocyte counts remained severely
suppressed (median 4/ml, IQR 1.25-9.5, p,0.001) in 15 patients
that were available for analysis (Figure 2 b). In five patients the
median observation time was 30 months (26–51 months) and the
median peripheral B cell number 8/ml. One of these patients had
a complete reconstitution (154 B cells/ml), while three patients had
B cell counts below 10/ml. CYC sum dose and frequency of MMF
used as maintenance therapy after RTX had no significant
influence on peripheral B lymphocyte numbers after the median
observation time of 20 months (data not shown).
Discussion
Recently, rituximab has been reported to be an efficacious and
well tolerated treatment for AAVs [6,18–20]. As CYC can deplete
B lymphocytes, the long-term impact of RTX on serum
immunoglobulins and the peripheral B lymphocyte compartment
is of major interest in patients previously treated with CYC. In our
patients treatment with CYC resulted in a decrease of all
immunoglobulin isotypes, but median Ig concentrations remained
within the normal range. We observed that particularly IgG and
IgM isotypes of patients previously treated with CYC and
subsequently receiving RTX further decreased significantly,
whereas the drop in IgA serum concentration did not reach
Figure 1. Effect of CYC treatment and CYC treatment followed by RTX on serum Ig concentrations in AAV patients. Vertical dashed
lines indicate the time of treatment with CYC (A) and CYC followed by RTX (B). Black circles stand for IgG concentrations, open circles for IgA
concentrations, and black triangles for IgM concentrations. Vertical bars on the right represent the normal ranges of IgG, IgA and IgM serum
concentrations. Median 6 SE are reported.
doi:10.1371/journal.pone.0037626.g001
Serum Immunoglobulins after RTX in AAV Patients
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37626Serum Immunoglobulins after RTX in AAV Patients
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declined to concentrations below 7.0 g/L and in 21% to
concentrations below 5.0 g/L. In all patients with IgG concentra-
tions below 5.0 g/L Ig replacement therapy had to be started
because of clinically relevant infections. Furthermore, in four out
of these patients testing for specific antibodies to pneumococcal
polysaccharides revealed a defect in the antibody response. Our
data indicate that in patients with AAVs that had previously been
treated with CYC, RTX can lead to a further significant decline in
serum immunoglobulin concentrations. The reasons for this
finding are not clear. An additive effect of CYC and RTX as
well as a synergy between RTX and maintenance immunosup-
pression might be causative. On the other hand, in our study
maintenance immunosuppressive therapy was also used in patients
that had only received CYC but no RTX. RTX induced
hypogammaglobulinemia is rare in e.g. patients with rheumatoid
arthritis (RA), and mainly affects the IgM isotype [20,21]. This
may indicate that there are indeed differences in Ig production
and response to RTX in AAVs compared to other autoimmune
diseases. In AAVs Ig production might be more dependent on
a continuous differentiation of B cells into short-lived plasma cells,
a process that would efficiently be targeted by RTX. Further
studies with patients treated with RTX only have to address this
issue. While not systematically assessed, some studies described
a decrease in serum immunoglobulin concentrations after RTX
therapy of AAV patients [22–25]. A recent survey of RTX therapy
in 65 AAV patients comparable to our patients with regard to
disease duration, previous immunosuppressive treatment and
cumulative CYC doses reported a significant decrease in IgM
concentrations [26]. Different from our results the median follow-
up IgG concentration did not change significantly from baseline.
However, no information is given on the exact time and the
number of patients included into the IgG analysis. The reported
IgG range of 1.5-28.9 g/L at baseline and 3.7-17.4 g/L at follow-
up indicates profoundly decreased IgG concentrations in at least
some patients. Interestingly, previous publications described
a severe hypogammaglobulinemia in patients with lymphoma
treated with CYC and RTX containing chemotherapies [27,28].
Therefore our study is of considerable importance, as it is the first
to report a statistically significant and clinically relevant decline in
serum Ig concentrations in a substantial number of chronic AAV
patients treated with CYC and RTX. The decrease in Ig
concentrations is reflected by a prolonged depletion of B cells
after CYC and RTX treatment. In patients with RA and Sjo ¨gren’s
syndrome treated with RTX peripheral B cell reconstitution
usually starts within six to nine months after therapy [29,30].
Another retrospective analysis reported a repopulation of the
peripheral B cell compartment by 11 months in 28 out of 45
patients [26]. Unfortunately, there is no information on absolute B
cell numbers and the criteria for B cell depletion was set to
,0.02610
9 cells/L, while $0.02610
9 B cells/L was the criteria
for B cell repopulation. That rather indicates the period of time
until B cells were again detectable but does not give sufficient
information on reconstitution to normal of the peripheral B cell
compartment. Our retrospective study has some limitations. Not
all patients that were included into the study were available for Ig
and B cell analyses at the analysed time points. The use of various
different maintenance therapies after CYC and RTX – even while
not statistically different between the groups – may still be
a confounding factor. Furthermore, our study cannot provide
a definite answer to the question whether there is a synergistic
mode of action of RTX and CYC or maintenance immunosup-
pressive therapies. Larger cohorts of AAV patients with extended
observation periods are needed to confirm our results and to assess
long-term effects of CYC/RTX treatment on peripheral B cells
and Ig serum concentrations. Furthermore, prospective, random-
ized trials have to answer at what time point AAV patients should
be retreated with RTX, whether a critical cumulative CYC dose
exists that should caution against subsequent RTX therapy, and
whether maintenance immunosuppressive therapy is needed after
RTX treatment.
In summary, we report on a long-lasting decrease of serum Ig
and a retarded peripheral B cell reconstitution in AAV patients
treated with RTX after previous CYC therapy. Therefore, in
AAVs treated with CYC and RTX serum Ig concentrations and B
cell counts need to be closely monitored. In case of increased
infections in patients with secondary hypogammaglobulinemia
immunoglobulin replacement therapy should be considered. RTX
monotherapy needs to be evaluated for its effect on the humoral
immunity of patients with AAVs and might be a treatment
alternative to a dual therapy with CYC and RTX.
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